Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET

Company Participants

Jon Patton - Director-Investor Relations and Communications

Matt Coffey - President and Chief Executive Officer

Thomas Heineman - Chief Medical Officer

Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.

Kirk Look - Chief Financial Officer

Conference Call Participants

Patrick Trucchio - H.C. Wainwright

Soumit Roy - JonesTrading

John Newman - Canaccord

Operator

Good morning, and welcome to Oncolytics Biotech's Second Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.

Jon Patton

Thank you, operator, and good morning, everyone. Earlier this morning, Oncolytics issued a press release providing recent operational highlights and financial results for the second quarter of 2023. A replay of today's call will be available on the Events & Presentations section of the Oncolytics website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A.

As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's focus, strategy and objectives, company's belief as to the potential and mode of action of pelareorep as a cancer therapeutic, company's plans regarding Precision Promise and the anticipated timing of entering into a definitive agreement in connection therewith, the company's plans and expectations regarding potential and registrational studies, the company's business development plans and strategies, and other statements related to anticipated developments in the company's business.

These statements are based on management's current expectations and beliefs and are subject to a number of factors, which involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward-looking statements.

Any new forward-looking statement in which Oncolytics expresses an expectation or beliefs as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that these statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, actions by regulatory agencies and those factors detailed in the company's filings with the SEDAR and the SEC. Oncolytics does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.